Biosimilars Help Stada Build First-Half Growth Momentum

Ustekinumab Rival To Stelara Is Leading Light Of Specialty Segment

 
• By Dave Wallace
  
Stada is accelerating its growth in 2025 (Shutterstock)

More from Earnings

More from Business